The best La Roche-Posay skincare products, including anti-aging options and picks for acne-prone, oily, dry, mature, ...

Our Grooming Editors and board-certified dermatologists tested over 100 face lotions to find the best ones for every skin ...

Almost every scene of the powerful "La Cocina" takes place in or just outside the kitchen of a Times Square tourist trap bluntly dubbed The Grill. It's one of those places that does a bit of ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...

Swiss Pharmaceutical giant Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) on Wednesday reaffirmed its full-year sales and earnings outlook after the company’s third-quarter sales results exceeded ...

Roche doesn’t think so. “I think we don’t see anything that should be slowing Vabysmo momentum down,” Teresa Graham, CEO of Roche Pharmaceuticals, said during a press conference Wednesday ...

Roche ROG-1.53%decrease; red down pointing triangle confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra ...

FRANKFURT, Oct 23 (Reuters) - The CEO of Roche (ROG.S), opens new tab said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the ...

UCB will ad­vance its an­ti-tau an­ti­body for Alzheimer’s dis­ease so­lo af­ter Roche and Genen­tech walked away from the as­set known as bepranemab.

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.